These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1486 related articles for article (PubMed ID: 22204894)

  • 21. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients.
    Seyedmardani SM; Aghdashi MA; Soltani S; Zonouz GK
    Curr Rheumatol Rev; 2022; 18(1):48-57. PubMed ID: 34636314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment.
    Zhao H; Lian Y
    Australas J Dermatol; 2015 Aug; 56(3):202-5. PubMed ID: 25817568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients].
    Ben Salem T; Tougorti M; Bziouech S; Lamloum M; Khanfir M; Ben Ghorbel I; Houman MH
    J Med Vasc; 2018 Feb; 43(1):29-35. PubMed ID: 29425538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of botulinum toxin A in the treatment of Raynaud's phenomenon in systemic sclerosis: A randomized self-controlled trial.
    Du W; Zhou M; Zhang C; Sun Q
    Dermatol Ther; 2022 Jul; 35(7):e15529. PubMed ID: 35441772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Botulinum Toxin A Treatment for Primary and Secondary Raynaud's Phenomenon in Teenagers.
    Quintana Castanedo L; Feito Rodríguez M; Nieto Rodríguez D; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
    Dermatol Surg; 2021 Jan; 47(1):61-64. PubMed ID: 32371783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon.
    Ennis D; Ahmad Z; Anderson MA; Johnson SR
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101684. PubMed ID: 33965340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botox therapy for ischemic digits.
    Neumeister MW; Chambers CB; Herron MS; Webb K; Wietfeldt J; Gillespie JN; Bueno RA; Cooney CM
    Plast Reconstr Surg; 2009 Jul; 124(1):191-201. PubMed ID: 19568080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
    Jokar MH; Baghbani B; Geraylow KR; Shariati J; Mehrad-Majd H; Mirfeizi Z; Hashemzadeh K
    Reumatologia; 2022; 60(6):392-398. PubMed ID: 36683833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
    Habib SM; Brenninkmeijer EEA; Vermeer MH; de Vries-Bouwstra JK; Velthuis PJ
    Dermatol Ther; 2020 Nov; 33(6):e14182. PubMed ID: 32794364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 25. Ischemic pain in the extremities and Raynaud's phenomenon.
    Devulder J; van Suijlekom H; van Dongen R; Diwan S; Mekhail N; van Kleef M; Huygen F
    Pain Pract; 2011; 11(5):483-91. PubMed ID: 21435165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Marked effect of botulinum toxin A for severe toe digital ulcers in a patient with systemic sclerosis].
    Nielsen JB; Hvid L; Olesen AB
    Ugeskr Laeger; 2014 Feb; 176(8A):V08130527. PubMed ID: 25350310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin.
    Quintana Castanedo L; Feito Rodríguez M; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
    Pediatr Dermatol; 2020 Jul; 37(4):681-683. PubMed ID: 32212180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.